Inhibitor Therapeutics, Inc.
INTI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001042418
No open-market purchases or sales by Inhibitor Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Inhibitor Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Inhibitor Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| McNulty James A | Chief Financial Officer | 19,901,057 | Aug 4, 2026 | 1 |
| Black Robe Capital LLC | 10% Owner | 19,901,057 | Aug 4, 2026 | 1 |
| Osman Ronald E | Director, 10% Owner | 23,614,985Indirect | Aug 4, 2026 | 1 |
| Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012 | 10% Owner | 23,614,985Indirect | Aug 4, 2026 | 1 |
| Yanez Michelle | Director | 1,221,271 | Aug 4, 2026 | 1 |
| Sears Samuel P Jr | Director | 1,229,543 | Aug 4, 2026 | 1 |
| Odonnell Francis E Jr | Chief Executive Officer | 150,000 | Aug 4, 2026 | 1 |
| Jerman Michael Allen | Director | 180,411 | Jun 24, 2026 | 1 |
| Vasisht Niraj | Director | 200,000 | Jun 1, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.